MannKind Gestione
Gestione criteri di controllo 3/4
MannKind Il CEO è Michael Castagna, nominato in May2017, e ha un mandato di 7.5 anni. la retribuzione annua totale è $ 7.07M, composta da 9.9% di stipendio e 90.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.83% delle azioni della società, per un valore di $ 15.60M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.3 anni e 4.8 anni.
Informazioni chiave
Michael Castagna
Amministratore delegato
US$7.1m
Compenso totale
| Percentuale dello stipendio del CEO | 9.9% |
| Mandato del CEO | 7.5yrs |
| Proprietà del CEO | 0.8% |
| Durata media del management | 7.3yrs |
| Durata media del Consiglio di amministrazione | 4.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$22m |
| Jun 30 2024 | n/a | n/a | US$12m |
| Mar 31 2024 | n/a | n/a | US$8m |
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
| Sep 30 2018 | n/a | n/a | -US$110m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$131m |
| Dec 31 2017 | US$1m | US$459k | -US$117m |
Compensazione vs Mercato: La retribuzione totale di Michael ($USD 7.07M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.34M ).
Compensazione vs guadagni: La retribuzione di Michael è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Michael Castagna (47 yo)
7.5yrs
Mandato
US$7,068,114
Compensazione
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$7.07m | 0.83% $ 15.6m | |
| Chief Operating Officer | 1.7yrs | US$2.74m | 0.025% $ 478.2k | |
| Executive VP | 22.8yrs | US$2.34m | 0.17% $ 3.1m | |
| Executive VP and Chief People & Workplace Officer | 7.9yrs | US$2.22m | 0.22% $ 4.1m | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| Executive Vice President of Technical Operations | 2.1yrs | US$1.12m | 0.035% $ 650.2k | |
| VP of Investor Relations & Treasury | 7.3yrs | US$519.59k | Nessun dato | |
| Senior Vice President of Worldwide Regulatory Affairs | 19.1yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 7.3yrs | US$921.51k | Nessun dato | |
| Executive VP of Research & Development and Chief Medical Officer | 1.5yrs | Nessun dato | 0.070% $ 1.3m |
7.3yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di MNKD è esperto e expertise (durata media dell'incarico 7.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$7.07m | 0.83% $ 15.6m | |
| Independent Director | 21.1yrs | US$241.73k | 0.043% $ 805.2k | |
| Chairman Emeritus | less than a year | US$240.64k | 0.096% $ 1.8m | |
| Independent Director | 6yrs | US$226.73k | 0.010% $ 188.3k | |
| Independent Director | 20.9yrs | US$229.23k | 0.0054% $ 101.6k | |
| Independent Director | 4.8yrs | US$233.14k | 0.064% $ 1.2m | |
| Independent Chairman | 9.5yrs | US$255.64k | 0.0089% $ 166.3k | |
| Independent Director | 3.9yrs | US$221.73k | 0.039% $ 727.8k | |
| Member of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Director | less than a year | US$2.34m | 0.20% $ 3.7m | |
| Independent Director | 4.7yrs | US$221.73k | 0.040% $ 752.7k | |
| Member of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato |
4.8yrs
Durata media
64.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MNKD sono considerati esperti (durata media dell'incarico 4.8 anni).